



International Alliance for  
Biological Standardization

## 4th Conference on Next Generation Sequencing for Adventitious Virus Detection in Biologics for Humans and Animal

Frankfurt, Germany  
December 3-5, 2024

### **Next Generation Sequencing: Validation, Regulatory Approval and Implementation of NGS as an alternative In Vivo Testing for Live Attenuated Influenza Vaccine**

Next Generation Sequencing (NGS) has been proven to address some of the limitations of the current testing methods for adventitious agents testing in biologics. NGS is recognized as a powerful technology with capabilities for broad virus detection, this addresses the challenges through validation, contamination control approach in vaccine manufacturing and eventual approval for the use of NGS as an alternative to the traditional In Vivo assay for lot release testing of a flu vaccine. This will also include data from 12 months of utilising NGS as a lot release assay as a replacement of the In vivo assay

This presentation summarises the efforts taken to replace the in vivo adventitious agents lot release test for Live Attenuated Influenza Vaccine with the NGS adventitious agent detection assay.

